NCT04849182View on ClinicalTrials.gov

Vertistop® D and Vertistop® L in Preventing Recurrence of High-recurrence BPPV

NACompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

December 4, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

November 3, 2020

Conditions
Benign Paroxysmal Positional Vertigo (BPPV)
Interventions
DIETARY_SUPPLEMENT

Vertistop D

Food supplement containing alpha-lipoic acid, carnosine, zinc, vitamin D3 and vitamins of group B, 1 tablet/day before meals

DIETARY_SUPPLEMENT

Vertistop L

Food supplement containing alpha-lipoic acid, carnosine, zinc and curcumin, 2 tablets/day (morning and evening)

Trial Locations (1)

75100

"Policoro Hospital Giovanni Paolo II", Matera

All Listed Sponsors
lead

Azienda Sanitaria Locale di Matera

OTHER

NCT04849182 - Vertistop® D and Vertistop® L in Preventing Recurrence of High-recurrence BPPV | Biotech Hunter | Biotech Hunter